Established safety profile in advanced NSCLC

Selected ARs with a difference of ≥5% for all grades or ≥2% for Grade 3-4 toxicity between treatment groups in the phase III trial

Selected adverse reactions in non-small cell lung cancer
a508 patients assessed in ABRAXANE/carboplatin-treated group.
b514 patients assessed in paclitaxel injection/carboplatin-treated group.
c513 patients assessed in paclitaxel injection/carboplatin-treated group.
dPeripheral neuropathy is defined by the Medical Dictionary for Regulatory Activities (MedDRA) v14.0 Standardized MedDRA Query (SMQ) neuropathy (broad scope).

Established safety profile in advanced NSCLC

Selected ARs with a difference of ≥5% for all grades or ≥2% for Grade 3-4 toxicity between treatment groups in the phase III trial

Selected adverse reactions in non-small cell lung cancer

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.